Introduction
Worldwide, the number of travelers is increasing substantially. 1.3 billion trips were made in 2017, an increase of 5% from the previous year [1] . Of those travelers, 323 million went to Asia and the Pacific regions with Southeast Asia facing the highest growth [1] . In addition, there is a continuous increase in older travelers with clinically significant co-existing conditions, such as diabetes, chronic lung, liver-and kidney disease, and cystic fibrosis as well as patients on immune-suppressing medications [2] [3] [4] . Any traveler exposed to contaminated soil and/or water due to outdoor activities can be infected with the Gramnegative environmental saprophyte Burkholderia pseudomallei and may consequently acquire melioidosis [5, 6] .
Melioidosis is an emerging tropical infectious disease and endemic in Southeast Asia and Northern Australia [5] [6] [7] . New evidence suggests that B. pseudomallei is more widely present than previously thought; predicted worldwide human melioidosis cases are 169,000 each year with a mortality of up to 50% [8] . The incubation period of melioidosis is generally 1-21 days [9] . However, the disease can also remain latent for up to 29 years [5] . Disease presentation can vary from skin abscesses to pneumonia and fulminant sepsis and can be acute (85%) or chronic (11%) [5] . Melioidosis often mimics other diseases (e.g. tuberculosis or cancer), has an uncommon presentation in temperate countries, and can be missed with standard microbiology techniques [5] . As a result, the disease is frequently misdiagnosed [5, 7] . Up to 80% of patients with melioidosis have an underlying illness that makes them susceptible to acquire this life-threatening infection [5] . Individuals with diabetes mellitus, the most common risk factor, which is present in more than 50% of all patients with melioidosis, have a 12-fold higher risk to acquire melioidosis compared to non-diabetics [5, 10] .
Front-line clinicians in non-endemic countries need to be aware that fever in returning travelers may signal melioidosis [2] . Microbiologists should be aware of this condition, recognize the characteristics of B. pseudomallei, and be familiar with the work-up of any oxidase-positive Gram-negative rod isolated from samples from anyone who has spent time in an melioidosis-endemic area [11] . This is further underscored by the classification of B. pseudomallei by the Centers for Disease Control and Prevention as a Tier 1 Select Agent. Melioidosis therapy consists of a prolonged antibiotic treatment course; an intravenous phase of two weeks (carbapenem or ceftazidime) followed by an oral eradication phase of three to six months (trimethoprim-sulfamethoxazole (TMP-SMX), or amoxicillin-clavulanic acid) depending on disease presentation [5] . No vaccine for melioidosis is currently available [12] . Therefore, preventive measures are key to avoiding infection. In Thailand, Limmathurotsakul et al. attempted to produce evidence-based guidelines for the prevention of melioidosis [13] . However, at present, no advice is generally given to tourists, but this could include measures targeted at risk groups, such as the use of waterproof shoes when walking in wet soil, or the advice to stay indoors during periods of heavy wind and rain [7, 14] . Here, we provide the first retrospective surveillance study of known imported melioidosis cases in a non-endemic country, The Netherlands, for a 25-year period.
Material and methods

Identification of cases
A melioidosis case was defined as the presence of an infection as determined by the primary physician and a confirmed positive B. pseudomallei culture [7] . Together with the Dutch National Institute for Public Health and the Environment (RIVM), we identified melioidosis cases from 1990. The RIVM offers laboratory identification and/or confirmation of cultured bacteria to all medical microbiological laboratories in the country [15] . This procedure consists of multiple phenotypical tests, fatty acid analysis, 16S rDNA sequence analysis, matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF), and a species-specific test based on three PCRs [15] . Furthermore, some melioidosis cases were reported in the weekly reports of The Netherlands Early Warning Committee of the RIVM.
In The Netherlands disease notification of melioidosis is not mandatory, in contrast to some other countries such as the United Kingdom. Therefore, we contacted all microbiology laboratories known by the Dutch Society for Medical Microbiology (NVVM) and the RIVM. We asked all Dutch laboratories to perform a systematic search in their system for any B. pseudomallei positive culture between 2003 and 2018. Several cases identified by laboratories before 2003 were also accepted into the analysis. If laboratories were unable to perform a search of the last 15 years due to data availability or altered laboratory systems, a 
Ethics and statistical analysis
Since the study was retrospective in nature and only involved data derived from medical records, an exemption from the need for consent was provided by the Medical Ethics Review Committee of the Amsterdam UMC, location Academic Medical Center (reference number W17_470 # 17.543). Under Dutch law, the secondary use of anonymized human tissue specimens is not subject to ethical review or patient consent, following the "Code of conduct for responsible use of human tissue" designed by the Federation of Dutch Medical Scientific Societies in 2011 [16] . Patient's written consent was obtained for radiological images presented. Statistical analysis was performed using Prism/R (version 3.5.1). Non-parametric quantitative variables are presented as median and range.
Results
Case identification
The response rate for the 55 Dutch microbiology laboratories was 100%. Seventeen laboratories identified 25 cases between 2003 and 2018 by tracking positive B. pseudomallei culture results. Seven laboratories were unable to retrieve information prior to 2007. Four laboratories were able to retrieve cases from more than 15 years ago (1990, 1994, 1999, and 2002, respectively) . Another 15 cases from the period 1990 to 2018 were identified through the existing informal registry and network of the RIVM. An extensive literature search from 1985 to 2018 identified another ten cases. Duplicates (n = 20) were removed. In total, 33 melioidosis patients were included in the study ( Fig. 1 ).
Epidemiology and clinical features
Characteristics of returned travelers recorded with a confirmed B. pseudomallei infection (n = 33) are listed in Table 1 . A complete list of every patient is provided in Supplementary Table S2 . The median age of patients was 54 years (range 21-83). Twenty-three patients (70%) were male. All patients resided in The Netherlands, except one woman who was born and lived in Goa, India, and was on holidays in The Netherlands when the diagnosis was established (case no. 2 Supplementary  Table S2 ). Twenty-three patients (70%) had one or more risk factors, namely diabetes (n = 8), smoking (n = 7), cystic fibrosis (n = 3), excessive alcohol consumption (n = 3), chronic kidney disease (n = 2), chronic liver disease (n = 2), chronic obstructive pulmonary disease (COPD) (n = 1), non-Hodgkin lymphoma (n = 1), and methotrexate and prednisone use (n = 1).
Most patients acquired the infection in Thailand (52%, n = 17) followed by Brazil (6%, n = 2), Australia, Cambodia, Indonesia, Myanmar, India, and Vietnam (all n = 1; Table 2 ). Some patients (18%, n = 6) visited multiple countries and therefore the exact country of Supplementary Table S2 ) [17, 18] . Another patient, an 83-year old female, developed clinical evidence of melioidosis two years after a trip to Panama (case no. 29 Supplementary Table S2 ). Eighteen patients reported contact with soil or water e.g. one patient showered with unchlorinated water (case no. 6 Supplementary Table S2 ). In addition, two of those eighteen patients reported traumatic injuries; one patient exhibited hematomas after a collapse and another suffered from a distal radius fracture after a motorcycle accident. Two patients reported leech bites before the occurrence of disease symptoms. For full details see Supplementary Table S2 .
The time between onset of symptoms and presentation to the hospital ranged from 1 to 168 days (median 8). Most patients exhibited fever (n = 20), cough/dyspnea (n = 15), and malaise/fatigue (n = 13). Thoracic pain or weight loss was reported in six patients. In total, 29 patients (88%) were admitted to the hospital. Pneumonia, skin and softtissue infection (SSTI), and genitourinary infections (including prostatitis) were the most common manifestations of disease occurring in respectively 58% (n = 19), 18% (n = 6), and 18% (n = 6) of travelers. Interestingly, several patients had notable isolated infections; one with a prostate abscess, two patients with lymphadenitis, and one patient with an abscess of the chest wall (respectively case no 7, 10, 13, 21 Supplementary Table S2 ).
Infection was often multi-focal. Twelve (36%) of the patients presented with or progressed to sepsis and/or septic shock ( Table 1 , Fig. 2 ). Rare disease presentations included melioidosis of the ear, thyroid gland, adrenal gland, encephalitis and meningitis, and mycotic aneurysm (respectively case no. 6, 33, 23, 31 and 30 Supplementary Table  S2 ). Fig. 3 provides characteristic computed tomography (CT), positron emission tomography (PET-CT), and magnetic resonance imaging (MRI) images, as well as a chest X-ray and an angiography of different foci of infection in selected patients with melioidosis.
Microbiology
All 33 identified patients had a positive B. pseudomallei culture. Specimens most frequently positive were blood (n = 17, 52%) and sputum (n = 14, 42%; Table 3 ). B. pseudomallei was also isolated from (n = 1), bilateral otitis externa (n = 1), mycotic aneurysm (n = 1), polyarthritis (n = 1), and the thyroid gland (n = 1). g Initial intensive intravenous therapy consisted of ceftazidime (n = 22), meropenem (n = 9) or imipenem (n = 1) followed by subsequent eradication therapy with oral amoxicillin/clavulanic acid (n = 8), TMP-SMX (n = 21), and/or doxycycline (n = 8) to prevent recrudescence or relapse of the disease. h One patient was admitted 60 days in the hospital and 275 days in a rehabilitation centre. i Several patients developed severe post-infectious sequelae, including acute kidney failure requiring dialysis, intravenous catheter-associated candidemia, critical illness neuropathy requiring prolonged rehabilitation, and purpura fulminans following severe necrosis of fingers and toes requiring amputation and prolonged rehabilitation (all n = 1). , genitourinary samples including prostate biopsies (n = 6), SSTI derived pus (n = 6), lymph node aspirates or biopsies (n = 4), intra-abdominal abscesses (n = 2), cerebrospinal fluid (CSF) (n = 1), ear swab (n = 1), pleural fluid (n = 1), and biopsies from the thyroid gland (n = 1). Thirteen cases were confirmed with 16S rDNA sequencing in combination with classical phenotypical tests, (including API20 NE) and fatty acid analysis [15] . After 2003, species specific PCRs [15] were added (n = 12). Two cases before 1996 were only confirmed by classical phenotypical tests (see Table 3 and Supplementary Table S2 for details). B. pseudomallei is generally resistant to gentamicin and colistin (polymyxin E) and susceptible to amoxicillin/clavulanic acid [5] . All isolates followed these antibiotic patterns except five which showed resistance to amoxicillin/clavulanic-acid (n = 3, case no. 3, 19 and 27 Supplementary Table S2 ) and trimethoprim/sulfamethoxazole (TMP-SMX, n = 2, case no. 2 and 17 Supplementary Table S2 ).
Treatment and hospitalization
Initial intensive intravenous therapy consisted of ceftazidime (n = 22), meropenem (n = 9) or imipenem (n = 1) followed by subsequent eradication therapy with oral amoxicillin/clavulanic acid (n = 8), TMP-SMX (n = 21) and/or doxycycline (n = 8) to prevent recrudescence or relapse of the disease. Median length of antibiotic therapy was 99 days (26-308), divided by a first period of 18 days (10-266) of intravenous treatment followed by 84 days (14-252) of oral treatment (Table 1 ). Of note, three patients were not empirically treated with melioidosis-covering antibiotics as initial regimen on presentation, as these patients died between 2 and 6 days after admission before melioidosis was diagnosed.
Seven patients experienced severe adverse effects of antimicrobial agents (TMP-SMX (n = 5, respectively case no. 7, 13, 16, 18, and 19 Supplementary Table S2 ) doxycycline (n = 1, case no. 22 Supplementary Table S2 ), imipenem and meropenem (n = 1, case no. 31 Supplementary Table S2 )) that warranted using an agent from another antibiotic class. These side effects included severe skin rash, ataxia, leucopenia/thrombocytopenia, proteinuria, and impaired liver function (see Supplementary Table S2 ). The median length of hospital stay was 21 days (1-335). Twelve patients required intensive care admission (median 4, 1-24 days) due to multi-organ failure including need for vasopressors and mechanical ventilation. Supplementary Table S2 for details of cases. 
Outcome
Overall mortality in this cohort of returning travelers with melioidosis was 12% (n = 4); these patients all suffered from therapy refractory sepsis and died within 4-112 days (median 10) after the start of symptoms and between 2 and 26 days (median 2) after hospital admission. Several patients developed severe post-infectious sequelae, including acute kidney failure requiring dialysis, intravenous catheterassociated candidemia, critical illness neuropathy requiring prolonged rehabilitation, and purpura fulminans leading to severe necrosis of fingers and toes requiring amputation and prolonged rehabilitation.
Repeat episodes of active melioidosis infection were observed in five patients (15%). One was possibly due to reinfection as this patient traveled again to Thailand, the country where he had contacted the disease just four months before (case no. 30 Supplementary Table S2 ). The other four cases were due to relapse as no recurrent travel was reported. Most repeat of active melioidosis infection occurred within the first year after primary disease display with a median duration of 252 days (28-465).
Three patients underwent autopsy. Fig. 4A -C shows lung, spleen, liver and bone marrow tissues obtained through autopsy of a 73-year old female who died after cardiopulmonary resuscitation after seven days of illness caused by bilateral pneumonia, which was complicated by septic shock and respiratory insufficiency requiring intubation and mechanical ventilation (case no. 23 Supplementary Table S2 ). Autopsy findings included severe bronchopneumonia with extensive tissue necrosis in both lungs (Fig. 4A) , accompanied by metastatic (micro)abscesses in the spleen (Fig. 4B left) , liver (Fig. 4B right) , bone marrow ( Fig. 4C left) , and adrenal glands (not shown). Post-mortem lung tissue cultures were positive for B. pseudomallei.
Several cases stand out because of their uniqueness or illustrative history; some of these are highlighted in Textbox 1 (see Supplementary  Table S2 ).
Discussion
This retrospective surveillance study provides a systematic overview of culture confirmed imported melioidosis cases in a non-endemic country for a 25-year period. In total, 33 cases were identified, although this number is probably an underreporting. Clinicians may not be aware of melioidosis, particularly, if first seen in non-specialized units after a long latency period and not clearly connected to previous travels. Moreover, disease manifestations are often nonspecific, especially at an early stage. This is underscored by our finding that three patients died before the correct diagnosis was made and thus before the start of administration of correct antibiotic regimens. Overall the burden of melioidosis in terms of mortality and morbidity of individual patients affected was substantial, with a case fatality rate of 12%. Moreover, in 30% of the cases, both short-and long-term sequelae were observed ranging from renal replacement therapy requiring dialysis to long-term rehabilitation due to amputation of fingers and toes.
In this study, 70% of the patients had one or multiple risk factors for melioidosis, such as diabetes and cystic fibrosis. This corresponds with changing traveler patterns wherein individuals with such risk factors are often able to travel (longer) and to more adventurous holiday destinations because of improved clinical management [2] . For example, the life expectancy of patients with cystic fibrosis is rising and due to an aging population more senior tourists are traveling. None of the travelers in this study were HIV-1 positive, which is in line with the notion that HIV is not a risk factor for the acquisition of melioidosis [5] . Additionally, excessive alcohol consumption (9%) and smoking (21%) were reported. Smoking has been earlier identified by some as an independent risk factor for melioidosis [20] and could potentially impair the host response to invading pathogens and enhance the risk of infection by inhalation [13] . Thirty percent of patients were not known or diagnosed with a risk factor, indicating that healthy people can also develop a severe B. pseudomallei infection, which is in line with earlier reports in both autochthonous cases and travelers [9, 21, 22] .
Our study further underscores the ability of B. pseudomallei to cause infection in virtually any organ. To our knowledge, we are the first to describe an adult patient with a bilateral otitis externa caused by B. pseudomallei. Additionally, B. pseudomallei infection was identified postmortem amongst other sites in the adrenal glands and the bone marrow (case no. 23 Supplementary Table S2 ) and in the thyroid gland (case no. 33 Supplementary Table S2 ). Infections of these organs are rarely reported [10, [23] [24] [25] and no clinical findings were reported to suggest involvement of the adrenal and thyroid gland in those patients.
The number of travelers to melioidosis endemic areas is substantially increasing. Half of the patients in our study had traveled to Thailand, resonating with Thailand being a popular travel destination welcoming 236,300 Dutch tourists in the year [26] . It remains challenging however to determine if the relative high number of melioidosis cases associated with travel to Thailand is a reflection of a high risk in that country or simply the number of people who holiday there. Moreover, we identified patients who traveled to Australia, Brazil [19] , Supplementary Table S2 . [15] . h Phenotypical tests included API20 NE (n = 15). i Two confirmed by a second method [15] . j Other Identification methods included fatty acid analysis (n = 12), and antiserum agglutination (n = 2). k Culture confirmed by RIVM (n = 1), culture identification by API20 NE not confirmed by RIVM (n = 1). Supplementary Table S2 ) presented with a one-month history of fatigue, subfebrile temperatures not exceeding 38°, and bilateral ear pain after traveling to Thailand (case no. 6 Supplementary Table S2 ). He was diagnosed with a bilateral otitis externa. His medical history revealed bilateral otosclerosis and an ear bone chain prosthesis on the right side. Bilateral ear swab cultures grew B. pseudomallei, which was confirmed by PCR. CT scan showed no signs of mastoiditis nor any foci in other body parts but did show wall thickening of the external ear canals. Daily showers with unchlorinated water on the countryside in Thailand might have been the source of infection. The patient was treated on an outpatient basis and fully recovered on ten days of meropenem via outpatient parenteral antibiotic therapy followed by three months of oral TMP-SMX. Another patient, a 69-year old male (case no. 3 Supplementary Table S2 ) with an unremarkable medical history, was admitted to the hospital with complaints of coughing, sub-febrile temperatures not exceeding 38°, and 12 kg weight loss after traveling to Thailand seven months earlier. A PET-CT showed an extensive confluent and abscess like mediastinal lymphadenopathy (Fig. 3C left) . Biopsies taken during mediastinoscopy showed lymph node tissue with extensive granulomatous inflammation with areas of confluent tissue necrosis (Fig. 4C right) . Culture of the pus yielded Gram-negative rods that were initially misidentified as B. thailandensis by MALDI-TOF because the Security Database was not used. PCR, however, confirmed the microorganism to be B. pseudomallei. He was treated with ceftazidime for two weeks followed by ten weeks of TMP-SMX. Soon thereafter, the CRP value increased again, and PET/CT-imaging still showed 18F-fludeoxyglucose (FDG) avid mediastinal lymphadenopathy, despite the patient being asymptomatic. At this time, treatment consisted of meropenem for six weeks followed by six months of TMP-SMX. Four months after completion of this second prolonged course of antibiotics the CRP levels rose again; meanwhile the patient remained asymptomatic. Consequently, a transbronchial ultrasound-guided fine-needle aspiration was performed. The cytology specimen again showed signs of granulomatous inflammation. Whilst cultures remained negative, PCR was positive for B. pseudomallei. CRP levels normalized spontaneously and it was decided to not treat the patient again but adopt a wait and see policy instead. Currently, 1.5 years after the second antibiotic course, the patient is in good health.
A complete description of all cases is provided in Supplementary Table S2 . The Gambia [17] , Indonesia, India [27] , Myanmar, and Panama. Melioidosis can remain latent up to almost three decades [5] and therefore relevant travel may have occurred before most recent travel. Recent studies in sub-Saharan Africa [28, 29] and Latin America [30] , including modeling studies [8, 31] , indicated that melioidosis is more widespread across the tropics than previously thought. This illustrates that returning travelers with melioidosis serve as sentinels for detecting the emergence of this disease in tropical countries not yet considered as endemic and, more importantly, for understanding the global movement of melioidosis across borders [2] . It should be noted that crossborder movement is not a new phenomenon, as was shown by a recent sequencing study indicating that B. pseudomallei was already being spread via trade routes from Australia via Africa to (South) America in the 17th-19th century [32] . The only well documented example of transmission of melioidosis to a temperate climate occurred in the mid-1970s in France. An unexpected outbreak of melioidosis in a zoo in Paris resulted in the spread to other zoos and equestrians clubs. A number of animals were culled and at least two humans succumbed because of melioidosis [33] .
Our study has several strengths. Multiple literature studies of melioidosis in travelers have been published [21, 22, 34, 35] ; however, to our knowledge this is the first systematic retrospective surveillance study in a non-endemic melioidosis country. This is reflected in the number of cases presented. A recent literature review of melioidosis cases imported into Europe included 77 patients [34] , yet with only four Dutch cases [34] . Existing surveillance networks such as Geo-Sentinel and EuroTravNet are powerful tools to gain insights into travel-related diseases [36] . However, with respect to melioidosis, only 21 cases have been identified within the whole of Europe by the EuroTravNet in the period 1998-2018 [Grobusch MP. Personal communication EuroTravNet. 15 January 2019]. EuroTravNet includes traveler's information only derived from institutions whose clinics (often specialized academic centers) are already linked to the network. We believe our study can potentially contribute to the further improvement and continuous expansion of such networks. Moreover, in most countries, no advice on melioidosis is given to travelers with specific risk factors who are going to endemic areas [3, 4] . Our study can contribute to the guidance of clinicians in the provision of such advice. The first evidence-based guidelines developed in Thailand propose that protection is required against inhalation, percutaneous inoculation, and contaminated food or water [13] . The Center for Disease Control in The Northern Territory of Australia has developed specific guidelines and advice regarding prevention measures, for example, avoiding swimming in fresh water during the rainy season in endemic areas for various risk groups (diabetes, excessive alcohol consumption, chronic lung, liver, and kidney disease) [14] . In addition, the Central Public Health Laboratory in London, United Kingdom, has formulated a melioidosis specific advice targeted at cystic fibrosis patients to avoid rural areas in endemic countries, especially during the rainy season and severe weather events [37] . Nonetheless, given the extent of global travel, the chance for any individual traveler to acquire melioidosis remains relatively small.
Several limitations to our efforts should be mentioned. Complete data capture was challenging because of the retrospective nature of our study. Furthermore, caution needs to be exercised in interpreting the rise in numbers over the years as long as denominators remain indeterminable, and the influence of factors improving the awareness of melioidosis remain unrecognized. There is a chance that melioidosis cases might have been missed as seven laboratories were unable to retrieve information before 2007. Moreover, as culture remains the gold standard to identify B. pseudomallei infection and has an estimated sensitivity of ∼60% [5] melioidosis cases might have been passed undetected. Due to the extended study period, not all laboratory identification methods were standardized. Of interest, some bacterial isolates showed resistance against amoxicillin/clavulanic acid and TMP-SMX. However, results should be interpreted with caution as the European Committee on Antimicrobial Susceptibility Testing (EUCAST) was only founded in 1997 and at the moment, no EUCAST standards for the assessment of B. pseudomallei resistance to recommended antibiotic therapies have been developed [38] . The same holds true for the Clinical and Laboratory Standards Institute (CLSI) in the US. Acquired resistance to antibiotics is rare [39] , indicating that the resistance rate we report in our study is likely an over estimation. More studies on B. pseudomallei antibiotic resistance together with the development of specific interpretive criteria are needed. Additionally, repeat episodes of active infection were observed in 15% of cases. Unfortunately, no sequence typing of bacterial isolates to enable distinction between relapse and reinfection was performed.
Conclusions
In conclusion, imported melioidosis is likely to increase in the light of rising numbers of travelers with a chronic condition (or who are otherwise immunocompromised), improvements in diagnostics, and increased vigilance towards the condition. This first systematic retrospective surveillance study in a non-endemic melioidosis country shows that imported cases can serve as sentinels to provide information about disease activity in areas visited and inform pre-travel advice and posttravel clinical management.
